Abstract | BACKGROUND: PATIENTS AND METHODS: DISCUSSION: The worsening experienced by our patient 1 week after the beginning of the treatment is comparable with the immune reconstitution syndrome occasionally observed in tuberculosis in immunocompromised hosts, thus raising the question of the potential value of continuing infliximab treatment. Recommendations are needed concerning the prevention and treatment of M. marinum infections in patients on anti- TNFalpha biotherapies.
|
Authors | A Guyot, E Begon, L Abramowitz, J Landry, E Marinho, V Descamps, B Crickx |
Journal | Annales de dermatologie et de venereologie
(Ann Dermatol Venereol)
Vol. 136
Issue 11
Pg. 806-10
(Nov 2009)
ISSN: 0151-9638 [Print] France |
Vernacular Title | Infection cutanée aiguë et nécrosante a Mycobacterium marinum chez un patient traité par infliximab pour une maladie de Crohn. |
PMID | 19917434
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Antibodies, Monoclonal
- Gastrointestinal Agents
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Crohn Disease
(drug therapy)
- Gastrointestinal Agents
(adverse effects, therapeutic use)
- Humans
- Infliximab
- Male
- Middle Aged
- Mycobacterium Infections, Nontuberculous
(chemically induced, drug therapy, pathology, surgery)
- Mycobacterium marinum
- Necrosis
- Skin Diseases, Bacterial
(chemically induced, drug therapy, surgery)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|